Bloomberg: Cambridge sees Pfizer pursuit as disrupting science hub

Makika Kitamura investigates the AstraZeneca and Pfizer bid and its consequences for Cambridge and the UK. Andy Cosh, Assistant Director at Centre for Business Research (CBR), Cambridge Judge Business School, says there is ‘a danger that the network of academic researchers, consultancies and biopharmaceutical companies that Cambridge has been building, largely based on personal contacts, “gets busted”, if the deal goes ahead.”

Read the full article [bloomberg.com]